Position in EW
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$814
-$387 QoQ
Shares Held
9
-40.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,285
of 1,310 holders
Holding Since
Dec 2021
13 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EW Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Jun 30, 2026Mascoma Wealth Management LLC holds $113,293 across 9 Medical Devices names. EW ranks #6 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABT |
Abbott Laboratories
|
526 | $47,729 | |
| 2 | SYK |
Stryker Corp
|
144 | $45,336 | |
| 3 | ZBH |
Zimmer Biomet Holdings, Inc.
|
100 | $8,609 | |
| 4 | GEHC |
GE HealthCare Technologies Inc.
|
128 | $8,193 | |
| 5 | MDT |
Medtronic plc
|
17 | $1,329 | |
| 6 | EW |
Edwards Lifesciences Corp
This page
|
9 | $814 | |
| 7 | UFPT |
Ufp Technologies Inc
|
2 | $530 | |
| 8 | STE |
STERIS plc
|
2 | $421 |
All Filings in EW
Export CSV
13 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $814 | 9 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $1,201 | 15 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $682 | 8 | Shares | Sole | 2026-02-04 | |
| 2024-06-30 | $8,775 | 95 | Shares | Sole | 2024-08-02 | |
| 2024-03-31 | $9,078 | 95 | Shares | Sole | 2024-05-02 | |
| 2023-12-31 | $7,243 | 95 | Shares | Sole | 2024-01-24 | |
| 2023-09-30 | $6,581 | 95 | Shares | Sole | 2023-10-13 | |
| 2023-03-31 | $29,451 | 356 | Shares | Sole | 2023-05-01 | |
| 2022-12-31 | $26,561 | 356 | Shares | Sole | 2023-01-24 | |
| 2022-09-30 | $45,033 | 545 | Shares | Sole | 2022-10-18 | |
| 2022-06-30 | $56,103 | 590 | Shares | Sole | 2022-07-14 | |
| 2022-03-31 | $73,221 | 622 | Shares | Sole | 2022-04-25 | |
| 2021-12-31 | $37,958 | 293 | Shares | Sole | 2022-01-21 | |
| No filing history on record for this holder in this stock. | ||||||